Literature DB >> 3569380

Pharmacokinetic profile of fosfomycin trometamol (Monuril).

G Segre, E Bianchi, A Cataldi, G Zannini.   

Abstract

The kinetics of fosfomycin in serum and in urine was studied in 5 healthy volunteers after intravenous administration of disodium fosfomycin and after oral administration of trometamol fosfomycin at 50 mg/kg. The presence of secondary peaks in serum kinetics, more evident after oral administration, requires the use of a compartmental model with enterohepatic recirculation to which all the data of each subject were simultaneously fitted. The following values of the various pharmacokinetic parameters were calculated: central volume 10.6 +/- 0.92 liters; bioavailability 0.58 +/- 0.04; delay time in the recirculation 2.00 +/- 0.92 h; half-life 2.43 +/- 0.31 h; total clearance 8.3 +/- 1.6 l/h; urinary clearance 7.0 +/- 0.9 l/h; peak level 32.1 +/- 3.0 micrograms/ml; time of the peak 2.2 +/- 0.44 h. The fosfomycin concentration in urine remains above 1,000 micrograms/ml for 12 h and above 100 micrograms/ml for 48 h. The oral kinetics of fosfomycin is dose-dependent, as shown by serum and urine kinetics in other 4 volunteers after oral administration of 2, 3, 4 and 5 g; the fraction of the dose excreted by urine goes from 50% for 2 g to 22% for 5 g.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3569380     DOI: 10.1159/000472864

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  21 in total

1.  Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers.

Authors:  E Wenzler; E J Ellis-Grosse; K A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

2.  Prophylactic chemotherapy with fosfomycin trometamol versus placebo during transurethral prostatic resection.

Authors:  L Baert; I Billiet; J Vandepitte
Journal:  Infection       Date:  1990       Impact factor: 3.553

Review 3.  Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 4.  Challenges of antibacterial discovery.

Authors:  Lynn L Silver
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

5.  Activity of fosmidomycin in an in vitro model of the treatment of bacterial cystitis.

Authors:  Y Kanimoto; D Greenwood
Journal:  Infection       Date:  1987 Nov-Dec       Impact factor: 3.553

6.  Fosfomycin trometamol: activity in vitro against urinary tract pathogens.

Authors:  D Greenwood
Journal:  Infection       Date:  1990       Impact factor: 3.553

7.  Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity.

Authors:  T Bergan
Journal:  Infection       Date:  1990       Impact factor: 3.553

8.  Fosfomycin trometamol: historical background and clinical development.

Authors:  G Gialdroni Grassi
Journal:  Infection       Date:  1990       Impact factor: 3.553

9.  Fosfomycin trometamol in a single dose versus norfloxacin for seven days in the treatment of uncomplicated urinary infections in general practice.

Authors:  J B Boerema; F T Willems
Journal:  Infection       Date:  1990       Impact factor: 3.553

10.  Comparative pharmacokinetics of tromethamine fosfomycin and calcium fosfomycin in young and elderly adults.

Authors:  F Borsa; A Leroy; J P Fillastre; M Godin; B Moulin
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.